Cipher Pharmaceuticals Inc.

OTCPK:CPHR.F Stock Report

Market Cap: US$239.2m

Cipher Pharmaceuticals Valuation

Is CPHR.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CPHR.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CPHR.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CPHR.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CPHR.F?

Key metric: As CPHR.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CPHR.F. This is calculated by dividing CPHR.F's market cap by their current earnings.
What is CPHR.F's PE Ratio?
PE Ratio15.1x
EarningsUS$15.86m
Market CapUS$239.23m

Price to Earnings Ratio vs Peers

How does CPHR.F's PE Ratio compare to its peers?

The above table shows the PE ratio for CPHR.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27x
ZYBT Zhengye Biotechnology Holding
77.4xn/aUS$216.5m
PROC Procaps Group
3.4xn/aUS$179.5m
BTMD biote
22x69.0%US$184.9m
SIGA SIGA Technologies
5xn/aUS$427.0m
CPHR.F Cipher Pharmaceuticals
15.1x9.4%US$347.8m

Price-To-Earnings vs Peers: CPHR.F is good value based on its Price-To-Earnings Ratio (15.1x) compared to the peer average (27x).

Price to Earnings Ratio vs Industry

How does CPHR.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.6xn/aUS$2.01b
KPRX Kiora Pharmaceuticals
2.2x0.2%US$12.09m
CNNC Cannonau
0.3xn/aUS$96.73k
SEEL.Q Seelos Therapeutics
0.0003xn/aUS$1.31k
CPHR.F 15.1xIndustry Avg. 18.4xNo. of Companies6PE01224364860+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CPHR.F is good value based on its Price-To-Earnings Ratio (15.1x) compared to the US Pharmaceuticals industry average (18.4x).

Price to Earnings Ratio vs Fair Ratio

What is CPHR.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CPHR.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.1x
Fair PE Ratio15.9x

Price-To-Earnings vs Fair Ratio: CPHR.F is good value based on its Price-To-Earnings Ratio (15.1x) compared to the estimated Fair Price-To-Earnings Ratio (15.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CPHR.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$9.37
US$11.79
+25.8%
10.1%US$13.13US$10.24n/a3
Jan ’26US$9.97
US$11.79
+18.3%
10.1%US$13.13US$10.24n/a3
Dec ’25US$10.63
US$12.00
+12.9%
10.1%US$13.37US$10.42n/a3
Nov ’25US$10.93
US$12.18
+11.4%
10.9%US$13.75US$10.49n/a3
Oct ’25US$10.92
US$12.03
+10.2%
7.3%US$12.65US$10.79n/a3
Sep ’25US$14.08
US$11.52
-18.2%
6.5%US$12.37US$10.55n/a3
Aug ’25US$8.88
US$9.86
+11.1%
22.8%US$12.27US$6.86n/a3
Jul ’25US$6.04
US$7.80
+29.1%
8.0%US$8.41US$6.95n/a3
Jun ’25US$6.50
US$7.80
+20.0%
8.0%US$8.41US$6.95n/a3
May ’25US$6.25
US$5.61
-10.2%
19.9%US$6.82US$4.13n/a3
Apr ’25US$5.98
US$5.61
-6.1%
19.9%US$6.82US$4.13n/a3
Mar ’25US$5.30
US$4.88
-8.0%
15.3%US$5.90US$4.13n/a3
Feb ’25US$4.41
US$4.14
-6.1%
11.1%US$4.68US$3.55US$9.373
Jan ’25US$4.19
US$3.95
-5.7%
9.6%US$4.35US$3.44US$9.973
Dec ’24US$4.70
US$3.95
-16.0%
9.6%US$4.35US$3.44US$10.633
Nov ’24US$3.14
US$3.22
+2.6%
7.2%US$3.53US$2.97US$10.933
Oct ’24US$3.18
US$3.22
+1.2%
7.2%US$3.53US$2.97US$10.923
Sep ’24US$2.91
US$3.22
+10.7%
7.2%US$3.53US$2.97US$14.083
Aug ’24US$2.79
US$3.22
+15.3%
7.2%US$3.53US$2.97US$8.883
Jul ’24US$2.70
US$3.22
+19.3%
7.2%US$3.53US$2.97US$6.043
Jun ’24US$2.88
US$3.22
+11.9%
7.2%US$3.53US$2.97US$6.503
May ’24US$2.47
US$3.00
+21.6%
3.0%US$3.09US$2.91US$6.252
Apr ’24US$2.47
US$3.00
+21.6%
3.0%US$3.09US$2.91US$5.982
Mar ’24US$2.74
US$3.08
+12.5%
3.0%US$3.18US$2.99US$5.302
Feb ’24US$2.54
US$3.08
+21.4%
3.0%US$3.18US$2.99US$4.412
Analyst Price Target
Consensus Narrative from 3 Analysts
US$11.51
Fair Value
18.6% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 04:27
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cipher Pharmaceuticals Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeByron Capital Markets
Prakash GowdCIBC Capital Markets
David NovakCormark Securities Inc.